

scPharmaceuticals™

\$50 Million
Follow-On Offering

svb Securities
Lead-Left Bookrunner
November 2022

SVB Securities Serves as Lead-Left Bookrunner for scPharmaceuticals (Nasdaq: SCPH) \$50.0 Million Follow-On Offering

Key Transaction Highlights

- Confidentially marketed deal that publicly launched November 21st post-close and priced Tuesday, November 22nd pre-open
- Deal consisted of 6,620,000 shares of common stock at a price of \$5.25 per share, representing a 13.8% discount to last sale price, and, to an investor in lieu of common stock, a pre-funded warrant to purchase up to 2,905,000 shares of common stock at a price of \$5.249 per underlying share
- scPharmaceuticals intends to use net proceeds from this offering to support the commercialization efforts for FUROSCIX, development of its pipeline, working capital and general corporate purposes
- This is SVB Securities' 3rd bookrun equity offering for scPharmaceuticals and 46th bookrun equity offering in 2022.

If you would like to unsubscribe from this distribution, click [here](#). If you would like to unsubscribe from all SVB Securities distributions, click [here](#).

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF SVB SECURITIES LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED FOR OR REDISTRIBUTED TO ANY OTHER PURPOSES. THESE SECURITIES HAVE BEEN SOLD. THIS EMAIL IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY, ANY SECURITIES.

BOSTON
53 State Street
40th Floor
Boston, MA 02109

CHARLOTTE
227 West Trade Street
Suite 2050
Charlotte, NC 28202

NASHVILLE
40 Burton Hills Boulevard
Suite 200
Nashville, TN 37215

NEW YORK
1301 Avenue of the Americas
12th Floor
New York, NY 10019

SAN FRANCISCO
255 California Street
12th Floor
San Francisco, CA 94111